INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93101, 'Exenatide', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93205/', '', 'Simvastatin, Metformin, Guar gum', 'Ulipristal, Norelgestromin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93102, 'Felbamate', 'Drospirenone', 'Major', 'RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.', 'DDInter', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93206/', '', 'Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93103, 'Fenoprofen', 'Drospirenone', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93207/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93104, 'Flibanserin', 'Drospirenone', 'Moderate', 'Concomitant use of hormonal contraceptives has been associated with increased adverse effects of flibanserin. The mechanism of interaction has not been established, but may partially involve inhibition of flibanserin metabolism. Flibanserin is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19. Some oral contraceptives are considered weak inhibitors of these isoenzymes.', 'DDInter', 'Caution is advised when flibanserin is used with hormonal contraceptives. Patients should be monitored for signs and symptoms of hypotension, syncope, and central nervous system depression.', 'Metabolism', 'Caution is advised when flibanserin is used with hormonal contraceptives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93208/', '', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol', 'Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Bromocriptine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93105, 'Fluconazole', 'Drospirenone', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', 'DDInter', 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93209/', '', 'Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, More', 'Megestrol acetate, Estetrol, Megestrol acetate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93106, 'Flurbiprofen', 'Drospirenone', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93210/', '', 'Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Lidocaine, Bacitracin, Chlorhexidine, More', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93107, 'Glimepiride', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93211/', '', 'Simvastatin, Metformin, Guar gum', 'Ulipristal, Norelgestromin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93108, 'Glipizide', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93212/', '', 'Simvastatin, Metformin, Guar gum', 'Ulipristal, Norelgestromin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93109, 'Glyburide', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93213/', '', 'Simvastatin, Metformin, Guar gum', 'Ulipristal, Norelgestromin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93110, 'Glycerol phenylbutyrate', 'Drospirenone', 'Moderate', 'Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4. Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo.', 'DDInter', 'Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and cyclosporine) should be done with caution and monitoring for reduced efficacy. Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.', 'Metabolism', 'Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93214/', '', 'Megestrol acetate, Estetrol, Etynodiol, Norgestrel, Megestrol acetate, Progesterone, Etynodiol, Norgestrel', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93111, 'Golimumab', 'Drospirenone', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93215/', '', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93112, 'Griseofulvin', 'Drospirenone', 'Major', 'RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance of the hormones due to induction of hepatic CYP450 enzymes by griseofulvin.', 'DDInter', 'Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with griseofulvin. Because griseofulvin has been shown to be teratogenic in animal studies and is capable of inducing aneuploidy (abnormal segregation of chromosomes following cell division) in mammalian cells in vitro and in vivo, it is particularly important that patients not become pregnant during treatment. Therefore, additional methods of birth control should be used during and for one month after griseofulvin therapy. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.', 'Metabolism', 'Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with griseofulvin.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93216/', '', 'Terbinafine, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93113, 'Guselkumab', 'Drospirenone', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93217/', '', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93114, 'Heparin', 'Drospirenone', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93218/', '', 'Betrixaban, Clopidogrel, Cilostazol, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More', 'Ulipristal, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Medroxyprogesterone acetate, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93115, 'Idelalisib', 'Drospirenone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', 'DDInter', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93219/', '', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93116, 'Indinavir', 'Drospirenone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', 'DDInter', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93220/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Megestrol acetate, Estetrol, Megestrol acetate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93117, 'Indomethacin', 'Drospirenone', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93221/', '', 'Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Misoprostol, Chondroitin sulfate, More', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93118, 'Infliximab', 'Drospirenone', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93222/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93119, 'Insulin human', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93223/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93120, 'Insulin aspart (aspart)', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93224/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93121, 'Insulin aspart (aspart protamine)', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93225/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93122, 'Insulin degludec', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93226/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93123, 'Insulin detemir', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93227/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93124, 'Insulin glargine', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93228/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93125, 'Insulin glulisine', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93229/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93126, 'Insulin human (inhalation, rapid acting)', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93230/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93127, 'Insulin human (isophane)', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93231/', '', 'Ulipristal, Norelgestromin, Norgestimate, Etynodiol, Desogestrel, Dienogest, Estetrol, Norgestimate, Dienogest, Etynodiol, Desogestrel', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93128, 'Insulin lispro', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93232/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93129, 'Insulin lispro (protamine)', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93233/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93130, 'Insulin human (regular)', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93234/', '', 'Ulipristal, Norelgestromin, Norgestimate, Etynodiol, Desogestrel, Dienogest, Estetrol, Norgestimate, Dienogest, Etynodiol, Desogestrel', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93131, 'Insulin human (zinc)', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93235/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93132, 'Insulin human (zinc extended)', 'Drospirenone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93236/', '', 'Ulipristal, Norelgestromin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93133, 'Irbesartan', 'Drospirenone', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93237/', '', 'Hydrochlorothiazide, Sacubitril, Aliskiren, Nebivolol', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Medroxyprogesterone acetate, Desogestrel, Dienogest, Estetrol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93134, 'Itraconazole', 'Drospirenone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', 'DDInter', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93238/', '', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Megestrol acetate, Estetrol, Megestrol acetate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93135, 'Drospirenone', 'Ivosidenib', 'Moderate', 'RECOMMENDED: Coadministration with ivosidenib may decrease the plasma concentrations of contraceptive hormones. The interaction has not been evaluated in pharmacokinetic studies. However, ivosidenib is an inducer of CYP450 3A4 and induces its own metabolism following multiple dosing.', 'DDInter', 'Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when used with ivosidenib. Female patients of reproductive potential receiving hormonal contraceptives should consider alternative or additional methods of contraception during treatment with ivosidenib.', 'Metabolism', 'Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when used with ivosidenib.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93239/', '', 'Estetrol', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Porfimer sodium, Niraparib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93136, 'Drospirenone', 'Ixekizumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93240/', '', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93137, 'Drospirenone', 'Ketoconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', 'DDInter', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93241/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Megestrol acetate, Estetrol, Megestrol acetate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93138, 'Drospirenone', 'Ketoprofen', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93242/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93139, 'Drospirenone', 'Lamotrigine', 'Moderate', 'Coadministration with estrogens or progestins may decrease the plasma concentrations and pharmacologic effects of lamotrigine due to induction of lamotrigine glucuronidation. Lamotrigine also has been shown to have little or no effect on the pharmacokinetics of contraceptive hormones, although measurement of serum FSH, LH, and estradiol has indicated some loss of suppression of the hypothalamic-pituitary-ovarian axis. Measurement of serum progesterone indicated no hormonal evidence of ovulation.', 'DDInter', 'Pharmacologic response and plasma lamotrigine levels should be monitored more closely whenever estrogen- and/or progestin-containing drugs are added to or withdrawn from therapy, and the lamotrigine dosage adjusted as necessary. The manufacturer''s labeling should be consulted for detailed dosage recommendations. Patients should be advised to contact their physician if they experience loss of seizure control or symptoms of lamotrigine toxicity such as ataxia, nystagmus, increased seizures, irregular heartbeat, and changes in mental status. In patients receiving oral contraceptives, gradual transient increases in lamotrigine levels will occur during the pill-free week for women not also taking an enzyme-inducing drug (e.g., carbamazepine, phenytoin, phenobarbital, primidone, rifampin). The increase in lamotrigine levels will be greater if the dose of lamotrigine is increased in the few days before or during the pill-free week. Although diminished contraceptive efficacy has not been reported, the possibility should be considered. Patients should be instructed to promptly report changes in their menstrual pattern.', 'Antagonism', 'Pharmacologic response and plasma lamotrigine levels should be monitored more closely whenever estrogen- and/or progestin-containing drugs are added to or withdrawn from therapy, and the lamotrigine dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93243/', '', 'Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More', 'Megestrol acetate, Ulipristal, Dienogest, Megestrol acetate, Dienogest', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93140, 'Drospirenone', 'Lapatinib', 'Moderate', 'Coadministration with lapatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these routes due to inhibition by lapatinib.', 'DDInter', 'Caution is advised if lapatinib must be used concurrently with medications that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-gp efflux transporter, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lapatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if lapatinib must be used concurrently with medications that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-gp efflux transporter, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93244/', '', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93141, 'Drospirenone', 'Larotrectinib', 'Moderate', 'Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.', 'DDInter', 'Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever larotrectinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects. Some authorities recommend avoiding concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93245/', '', 'Dienogest, Estetrol, Etynodiol, Dienogest, Etynodiol', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93142, 'Drospirenone', 'Lefamulin', 'Moderate', 'When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively.', 'DDInter', 'Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93246/', '', 'Dienogest, Estetrol, Etynodiol, Dienogest, Etynodiol', 'Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93143, 'Drospirenone', 'Lemborexant', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93247/', '', 'Norelgestromin, Norgestimate, Etynodiol, Desogestrel, Dienogest, Estetrol, Norgestimate, Dienogest, Etynodiol, Desogestrel', 'Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93144, 'Drospirenone', 'Lenalidomide', 'Major', 'Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use of lenalidomide. Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been observed at significantly increased rates when lenalidomide was coadministered with dexamethasone for the treatment of multiple myeloma.', 'DDInter', 'The use of estrogen-containing medications including combined oral contraceptive pills should be undertaken with caution in patients receiving lenalidomide, particularly multiple myeloma patients receiving lenalidomide with dexamethasone. Patients should be apprised of the increased risk of venous thromboembolic events if a combined oral contraceptive pill is chosen as one of two effective methods of contraception that must be used simultaneously and continuously for 4 weeks before, during (even in case of dose interruption), and for 4 weeks after lenalidomide therapy. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs. It is not known whether prophylactic anticoagulation or antiplatelet therapy may lessen the risk of venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of underlying risk factors. If a thromboembolic event occurs during therapy with lenalidomide, treatment must be discontinued and standard anticoagulation therapy started. Once anticoagulation is stabilized and complications of the thromboembolic event under control, lenalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of lenalidomide treatment.', 'Synergism', 'The use of estrogen-containing medications including combined oral contraceptive pills should be undertaken with caution in patients receiving lenalidomide, particularly multiple myeloma patients receiving lenalidomide with dexamethasone.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93248/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Norelgestromin, Norethisterone, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Etonogestrel, Norgestrel, Norethisterone, Megestrol acetate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93145, 'Drospirenone', 'Lesinurad', 'Moderate', 'RECOMMENDED: Coadministration with lesinurad may decrease the plasma concentrations of contraceptive hormones and reduce their effectiveness. The interaction has not been evaluated in pharmacokinetic studies. However, lesinurad is a weak inducer of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of contraceptive hormones. Lesinurad has been shown to induce the metabolism of other CYP450 3A4 substrates in interaction studies.', 'DDInter', 'Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when used with lesinurad. Female patients of reproductive potential receiving hormonal contraceptives should practice additional methods of contraception during treatment with lesinurad.', 'Metabolism', 'Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when used with lesinurad.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93249/', '', 'Megestrol acetate, Estetrol, Estradiol, Megestrol acetate, Progesterone, Estradiol', 'Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93146, 'Drospirenone', 'Letermovir', 'Moderate', 'Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. In vitro and in vivo studies have shown that both estrogens and progestins are partially metabolized by CYP450 3A4. Studies of letermovir with midazolam, a CYP450 3A4 probe substrate, have shown the net effect of letermovir on the CYP450 3A4 isoenzyme is moderate inhibition.', 'DDInter', 'Monitor estrogen/progestin therapy for altered pharmacologic response and adjust dosage(s) accordingly whenever letermovir is added to or withdrawn from therapy. When choosing an oral contraceptive, consider choosing an ethinyl estradiol-levonorgestrel product as this combination has been studied with letermovir and no clinically significant interaction has been found.', 'Metabolism', 'Monitor estrogen/progestin therapy for altered pharmacologic response and adjust dosage(s) accordingly whenever letermovir is added to or withdrawn from therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93250/', '', 'Ulipristal, Estetrol, Levonorgestrel, Ethinylestradiol, Levonorgestrel', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93147, 'Drospirenone', 'Linagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93251/', '', 'Ulipristal, Norelgestromin', 'Simvastatin, Metformin, Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93148, 'Drospirenone', 'Liraglutide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93252/', '', 'Ulipristal, Norelgestromin', 'Simvastatin, Metformin, Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93149, 'Drospirenone', 'Lisinopril', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93253/', '', 'Felodipine, Hydrochlorothiazide, Indapamide, Bisoprolol, Simvastatin, Lovastatin, Ezetimibe, Pravastatin, Niacin, Bempedoic acid, Indapamide, Fenofibrate', 'Ulipristal, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Medroxyprogesterone acetate, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93150, 'Drospirenone', 'Lixisenatide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93254/', '', 'Ulipristal, Norelgestromin', 'Simvastatin, Metformin, Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93151, 'Drospirenone', 'Lomitapide', 'Moderate', 'Coadministration with weak inhibitors of CYP450 3A4 including oral contraceptives may increase the plasma concentrations of lomitapide, which is primarily metabolized by the isoenzyme. Weak CYP450 3A4 inhibitors increase lomitapide exposure by approximately 2-fold according to the product labeling.', 'DDInter', 'The maximum recommended dosage of lomitapide is 30 mg daily when used in combination with weak CYP450 3A4 inhibitors including oral contraceptives. Likewise, if oral contraceptives are initiated during treatment with lomitapide, the dosage of lomitapide may require adjustment. Patients should be advised that hormone absorption from oral contraceptives may be incomplete if vomiting or diarrhea occurs while taking lomitapide, which would warrant the use of additional contraceptive methods, especially since lomitapide may be teratogenic.', 'Metabolism', 'The maximum recommended dosage of lomitapide is 30 mg daily when used in combination with weak CYP450 3A4 inhibitors including oral contraceptives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93255/', '', 'Ulipristal, Norelgestromin, Megestrol acetate, Estradiol, Medroxyprogesterone acetate, Estetrol, Etonogestrel, Megestrol acetate, Progesterone, Estradiol, Medroxyprogesterone acetate', 'Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Ezetimibe, Niacin, Fluvastatin, Gemfibrozil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93152, 'Drospirenone', 'Lonafarnib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', 'DDInter', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93256/', '', 'Dienogest, Estetrol, Etynodiol, Dienogest, Etynodiol', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93153, 'Drospirenone', 'Lorlatinib', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93257/', '', 'Estetrol', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93154, 'Drospirenone', 'Losartan', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93258/', '', 'Hydrochlorothiazide, Sacubitril, Aliskiren, Nebivolol', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93155, 'Drospirenone', 'Meclofenamic acid', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93259/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93156, 'Drospirenone', 'Mefenamic acid', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93260/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93157, 'Drospirenone', 'Meloxicam', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93261/', '', 'Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93158, 'Drospirenone', 'Methylphenobarbital', 'Moderate', 'RECOMMENDED: Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital. Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.', 'DDInter', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates. Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy. Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.', 'Metabolism', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93262/', '', 'Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93159, 'Drospirenone', 'Metreleptin', 'Moderate', 'Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.', 'DDInter', 'Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.', 'Metabolism', 'Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93263/', '', 'Megestrol acetate, Estetrol, Estradiol, Megestrol acetate, Progesterone, Estradiol', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93160, 'Drospirenone', 'Miconazole', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', 'DDInter', 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93264/', '', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More', 'Megestrol acetate, Dienogest, Estetrol, Megestrol acetate, Dienogest', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93161, 'Drospirenone', 'Mifepristone', 'Moderate', 'Mifepristone is a progesterone-receptor antagonist and will interfere with the effectiveness of hormonal contraceptives.', 'DDInter', 'When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, only nonhormonal contraceptive methods should be used. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).', 'Antagonism', 'When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, only nonhormonal contraceptive methods should be used.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93265/', '', 'Ospemifene, Prasterone, Raloxifene', 'Ulipristal, Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93162, 'Drospirenone', 'Miglitol', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93266/', '', 'Simvastatin, Metformin, Guar gum', 'Ulipristal, Norelgestromin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93163, 'Drospirenone', 'Miltefosine', 'Moderate', 'RECOMMENDED: The vomiting and/or diarrhea that commonly occur during miltefosine therapy may affect the absorption of oral contraceptives, potentially compromising their efficacy.', 'DDInter', 'Female patients receiving oral contraceptives should be advised to use additional non-hormonal or alternative method(s) of effective contraception if vomiting or diarrhea occurs during miltefosine therapy. This is particularly important because miltefosine may cause fetal harm. Teratogenicity and fetal death were observed in animals administered miltefosine at dosages lower than the recommended human dosage. Females of reproductive potential should use effective contraception during miltefosine therapy and for 5 months after completion of therapy.', 'Absorption', 'Female patients receiving oral contraceptives should be advised to use additional non-hormonal or alternative method(s) of effective contraception if vomiting or diarrhea occurs during miltefosine therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93267/', '', 'Ulipristal, Norelgestromin, Megestrol acetate, Estradiol, Medroxyprogesterone acetate, Estetrol, Etonogestrel, Megestrol acetate, Progesterone, Estradiol, Medroxyprogesterone acetate', 'Pentamidine, Nifurtimox, Benznidazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93164, 'Drospirenone', 'Mitotane', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93268/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Porfimer sodium, Niraparib, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93165, 'Drospirenone', 'Modafinil', 'Moderate', 'RECOMMENDED: Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of ethinyl estradiol and other contraceptive hormones. The mechanism involves induction of CYP450 3A4-mediated metabolism by modafinil and armodafinil.', 'DDInter', 'Women using hormonal contraceptives (including depot and implantable contraceptives) should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with modafinil or armodafinil. Alternative or additional methods of birth control are recommended during and for one month after treatment with modafinil or armodafinil. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.', 'Metabolism', 'Women using hormonal contraceptives (including depot and implantable contraceptives) should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with modafinil or armodafinil.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93269/', '', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93166, 'Drospirenone', 'Moexipril', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93270/', '', 'Felodipine, Hydrochlorothiazide, Indapamide, Bisoprolol', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93167, 'Drospirenone', 'Mycophenolate mofetil', 'Major', 'RECOMMENDED: Coadministration with mycophenolic acid may decrease the plasma concentrations and, theoretically, the efficacy of contraceptive hormones. The mechanism of interaction has not been established.', 'DDInter', 'Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms. Because use of mycophenolic acid is associated with an increased risk of pregnancy loss in the first trimester and congenital malformations, it is particularly important that female patients not become pregnant during treatment. An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) should be used in addition to the hormonal contraceptive of choice during the entire duration of mycophenolic acid therapy and for 6 weeks after discontinuation. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.', 'Others', 'Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93271/', '', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93168, 'Drospirenone', 'Mycophenolic acid', 'Major', 'RECOMMENDED: Coadministration with mycophenolic acid may decrease the plasma concentrations and, theoretically, the efficacy of contraceptive hormones. The mechanism of interaction has not been established.', 'DDInter', 'Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms. Because use of mycophenolic acid is associated with an increased risk of pregnancy loss in the first trimester and congenital malformations, it is particularly important that female patients not become pregnant during treatment. An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) should be used in addition to the hormonal contraceptive of choice during the entire duration of mycophenolic acid therapy and for 6 weeks after discontinuation. Input from a gynecologist or similar expert on adequate contraception should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.', 'Others', 'Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93272/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93169, 'Drospirenone', 'Nabumetone', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93273/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93170, 'Drospirenone', 'Nafcillin', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93274/', '', 'Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93171, 'Drospirenone', 'Naproxen', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93275/', '', 'Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, More', 'Ulipristal, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Medroxyprogesterone acetate, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93172, 'Drospirenone', 'Nateglinide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93276/', '', 'Simvastatin, Metformin, Guar gum', 'Ulipristal, Norelgestromin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93173, 'Drospirenone', 'Nefazodone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', 'DDInter', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93277/', '', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, More', 'Norelgestromin, Megestrol acetate, Etynodiol, Dienogest, Estetrol, Megestrol acetate, Dienogest, Etynodiol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93174, 'Drospirenone', 'Nelfinavir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', 'DDInter', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93278/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Megestrol acetate, Estetrol, Megestrol acetate, Progesterone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93175, 'Drospirenone', 'Neratinib', 'Moderate', 'RECOMMENDED: Coadministration with neratinib may reduce the efficacy of hormonal contraceptives. The mechanism for the potential interaction has not been established.', 'DDInter', 'Although the clinical significance of this interaction is unknown, caution is advised when neratinib is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with neratinib and for up to 1 month after discontinuing treatment. Women using hormonal contraceptives should add a barrier method. In addition, men receiving neratinib should use a barrier method of contraception during treatment and for 3 months after discontinuing treatment.', 'Antagonism', 'Although the clinical significance of this interaction is unknown, caution is advised when neratinib is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93279/', '', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93176, 'Drospirenone', 'Nevirapine', 'Moderate', 'RECOMMENDED: Coadministration with nevirapine may decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is nevirapine induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids.', 'DDInter', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with nevirapine. Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) nevirapine therapy. If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected. For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable. If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse). No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.', 'Metabolism', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with nevirapine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93280/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93177, 'Drospirenone', 'Olaparib', 'Moderate', 'RECOMMENDED: Coadministration with olaparib may decrease the plasma concentrations and efficacy of contraceptive hormones. The proposed mechanism is olaparib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.', 'DDInter', 'Some authorities recommend that women avoid pregnancy during olaparib treatment due to its potential teratogenic effects. In women of childbearing potential, alternative or additional non-hormonal methods of birth control should be considered during treatment and for one month after receiving the last dose of olaparib. Regular pregnancy tests are also recommended. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.', 'Metabolism', 'Some authorities recommend that women avoid pregnancy during olaparib treatment due to its potential teratogenic effects.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93281/', '', 'Ulipristal, Megestrol acetate, Estradiol, Medroxyprogesterone acetate, Estetrol, Megestrol acetate, Progesterone, Estradiol, Medroxyprogesterone acetate', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Porfimer sodium, Niraparib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93178, 'Drospirenone', 'Oxcarbazepine', 'Major', 'RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.', 'DDInter', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93282/', '', 'Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93179, 'Drospirenone', 'Oxtriphylline', 'Moderate', 'The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines. The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.', 'DDInter', 'Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives. Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen. Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.', 'Metabolism', 'Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93283/', '', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline', 'Megestrol acetate, Ulipristal, Estetrol, Medroxyprogesterone acetate, Megestrol acetate, Progesterone, Medroxyprogesterone acetate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93180, 'Drospirenone', 'Pegaspargase', 'Moderate', 'Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase''s hepatotoxicity, which may impair oral contraceptives'' hepatic clearance.', 'DDInter', 'The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.', 'Synergism', 'The use of oral contraceptives during asparaginase treatment is not recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93284/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Porfimer sodium, Niraparib, More', 'Ulipristal, Norelgestromin, Megestrol acetate, Estradiol, Estetrol, Etonogestrel, Megestrol acetate, Progesterone, Estradiol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93181, 'Drospirenone', 'Pentobarbital', 'Moderate', 'RECOMMENDED: Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital. Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.', 'DDInter', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates. Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy. Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.', 'Metabolism', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93285/', '', 'Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93182, 'Drospirenone', 'Perampanel', 'Moderate', 'RECOMMENDED: Coadministration with certain anticonvulsants, such as rufinamide and perampanel, may reduce the efficacy of contraceptive hormones. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity by the anticonvulsants.', 'DDInter', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants. In general, alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.', 'Metabolism', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93286/', '', 'Ulipristal, Megestrol acetate, Estradiol, Medroxyprogesterone acetate, Estetrol, Megestrol acetate, Progesterone, Estradiol, Medroxyprogesterone acetate', 'Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93183, 'Drospirenone', 'Perindopril', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93287/', '', 'Felodipine, Hydrochlorothiazide, Indapamide, Bisoprolol, Simvastatin, Lovastatin, Ezetimibe, Pravastatin, Niacin, Bempedoic acid, Indapamide, Fenofibrate', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93184, 'Drospirenone', 'Pexidartinib', 'Major', 'Coadministration with pexidartinib may decrease the plasma concentration and efficacy of contraceptive hormones. The proposed mechanism is increased clearance due to pexidartinib-mediated induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids.', 'DDInter', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with pexidartinib. Alternative or additional methods of birth control should be used during and for at least one month after the final dose of pexidartinib. In addition, male patients with female partners of reproductive potential should use effective contraception during and for at least one week after the final dose of pexidartinib. No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.', 'Metabolism', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with pexidartinib.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93288/', '', 'Estetrol', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93185, 'Drospirenone', 'Phenylbutazone', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93289/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93186, 'Drospirenone', 'Phenytoin', 'Major', 'RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.', 'DDInter', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93290/', '', 'Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93187, 'Drospirenone', 'Pioglitazone', 'Minor', 'Coadministration with another thiazolidinedione, troglitazone, has been shown to decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is induction of hormone metabolism via CYP450 3A4.There are no data on the use of contraceptive hormones with pioglitazone. Because pioglitazone may be a weak inducer of CYP450 3A4, product labeling recommends additional caution in women requiring contraception.Intrauterine systems are unlikely to be significantly affected because of their local action.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93291/', '', 'Simvastatin, Metformin, Guar gum', 'Ulipristal', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93188, 'Drospirenone', 'Piroxicam', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93292/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Fluocinolone acetonide, Cortisone, Hydrocortisone, More', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93189, 'Drospirenone', 'Pitolisant', 'Moderate', 'RECOMMENDED: Coadministration with pitolisant may decrease the plasma concentrations of contraceptive hormones. The proposed mechanism is induction of the CYP450 3A4-mediated metabolism of estrogens and progestins by pitolisant and its main metabolites.', 'DDInter', 'The manufacturer recommends that alternative, nonhormonal methods of effective contraception should be used during and for at least 21 days after pitolisant therapy.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93293/', '', 'Megestrol acetate, Estetrol, Estradiol, Medroxyprogesterone acetate, Megestrol acetate, Progesterone, Estradiol, Medroxyprogesterone acetate', 'Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93190, 'Drospirenone', 'Pomalidomide', 'Major', 'Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of pomalidomide. Deep venous thrombosis (DVT) and pulmonary embolism (PE) occur in patients with multiple myeloma treated with pomalidomide.', 'DDInter', 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide. Prophylactic antithrombotic measures should be considered after assessing underlying risk factors such as health history and concomitant medications. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.', 'Synergism', 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93294/', '', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Etonogestrel, Norgestrel, Norethisterone, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93191, 'Drospirenone', 'Posaconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', 'DDInter', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93295/', '', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93192, 'Drospirenone', 'Potassium acetate', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93296/', '', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', 'Calcium chloride, Zinc sulfate, Magnesium sulfate, Sodium acetate, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, Sodium bicarbonate, Sodium chloride, Ammonium chloride, Magnesium chloride', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93193, 'Drospirenone', 'Monopotassium phosphate', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93297/', '', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93194, 'Drospirenone', 'Potassium bicarbonate', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93298/', '', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93195, 'Drospirenone', 'Potassium chloride', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93299/', '', 'Calcium chloride, Zinc sulfate, Magnesium sulfate, Sodium acetate, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, Sodium bicarbonate, Sodium chloride, Ammonium chloride, Magnesium chloride', 'Ulipristal, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Medroxyprogesterone acetate, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93196, 'Drospirenone', 'Potassium gluconate', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93300/', '', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93197, 'Drospirenone', 'Potassium perchlorate', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93301/', '', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', 'Methimazole, Propylthiouracil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93198, 'Drospirenone', 'Pralsetinib', 'Moderate', 'RECOMMENDED: Coadministration with pralsetinib may render hormonal contraceptives ineffective. The mechanism for the potential interaction has not been established and there are no clinical data regarding the use of pralsetinib with hormonal contraceptives. Pralsetinib can cause fetal harm when administered to a pregnant woman.', 'DDInter', 'Until further data are available, females of reproductive potential should be advised to use effective non-hormonal contraception during treatment and for 2 weeks after the final dose. In addition, men receiving pralsetinib should use effective contraception during treatment and for 1 week after the final dose.', 'Others', 'Until further data are available, females of reproductive potential should be advised to use effective non-hormonal contraception during treatment and for 2 weeks after the final dose.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93302/', '', 'Megestrol acetate, Estetrol, Megestrol acetate', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93199, 'Drospirenone', 'Pramlintide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93303/', '', 'Simvastatin, Metformin, Guar gum', 'Ulipristal, Norelgestromin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (93200, 'Drospirenone', 'Primidone', 'Major', 'RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.', 'DDInter', 'Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/93304/', '', 'Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More', 'Estetrol', 1767369485);
